Peripheral T-cell Lymphoma Clinical Trial
Official title:
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma
Verified date | December 2023 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with relapsed or refractory T-cell non-Hodgkin lymphoma or Hodgkin lymphoma. CPI-613 may kill cancer cells by turning off their mitochondria, which are used by cancer cells to produce energy and are the building blocks needed to make more cancer cells. By shutting off mitochondria, CPI-613 may deprive the cancer cells of energy and other supplies needed to survive and grow. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CPI-613 with bendamustine hydrochloride may kill more cancer cells.
Status | Completed |
Enrollment | 16 |
Est. completion date | September 15, 2022 |
Est. primary completion date | April 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed T-cell NHL or classic HL (i.e., nodular sclerosis HL, mixed cellularity HL, lymphocyte rich classic HL, and lymphocyte depleted HL) that has relapsed from, or is refractory to, all standard therapies (including autologous transplantation) known to provide clinical benefit, but have not been treated with bendamustine for their lymphoma - Must have measurable disease (e.g., a tumor mass > 1 cm) - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Expected survival > 3 months - Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation - Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists - At least 2 weeks must have elapsed from any prior surgery - Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 3 x UNL (=< 5 x UNL if liver metastases present) - Bilirubin =< 1.5 x UNL - Serum creatinine =< 1.5 mg/dL or 133 µmol/L - "International normalized ratio" or INR must be =< 1.5 - No evidence of active infection and no serious infection within the past month - Mentally competent, ability to understand and willingness to sign the informed consent form Exclusion Criteria: - Known cerebral metastases, central nervous system (CNS) or epidural tumor - Having "currently active" second malignancy unrelated to HL or NHL, unless they have completed anti-cancer therapy, are in complete response and are considered by their physicians to be at less than 30% risk of relapse - Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs - Serious medical illness that would potentially increase patients' risk for toxicity - Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease) - History of abdominal fistula or gastrointestinal perforation =< 6 months prior to treatment with study drugs - Pregnant women, or women of child-bearing potential not using reliable means of contraception - Lactating females - Fertile men unwilling to practice contraceptive methods during the study period - Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients - Unwilling or unable to follow protocol requirements - Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction or symptomatic congestive heart failure - Patients with a history of myocardial infarction that is < 3 months prior to registration - Evidence of active infection, or serious infection within the past month - Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C - Patients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment - Requirement for immediate palliative treatment of any kind including surgery |
Country | Name | City | State |
---|---|---|---|
United States | Abramson Cancer Center | Philadelphia | Pennsylvania |
United States | Comprehensive Cancer Center of Wake Forest University | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | RR, derived from the modified IWG criteria and the International Cutaneous Lymphoma (Olsen criteria) for cutaneous lymphoma | RR and its 95% confidence interval will be assessed. RR and the possible correlation between RR and DCR vs. OS and PFS will be evaluated. | Up to 3 years | |
Other | DCR, derived from the modified IWG criteria and the International Cutaneous Lymphoma (Olsen criteria) for cutaneous lymphoma | DCR and its 95% confidence interval will be assessed. DCR and the possible correlation between RR and DCR vs. OS and PFS will be evaluated. | Up to 3 years | |
Other | OS | OS curves will be plotted using Kaplan-Meier methods. OS and the possible correlation between RR and DCR vs. OS and PFS will be evaluated. | Time from first dose of 6,8-bis(benzylthio)octanoic acid to death by any cause, assessed up to 3 years | |
Other | PFS | PFS curves will be plotted using Kaplan-Meier methods and median PFS will be examined. PFS and the possible correlation between RR and DCR vs. OS and PFS will be evaluated. | Time from first dose of 6,8-bis(benzylthio)octanoic acid to disease progression, assessed up to 3 years | |
Other | Bone marrow biopsy assessment | Bone marrow and possible correlation between CR vs. bone marrow biopsy assessments such as clear of infiltration of leukemic cells according to morphology, and/or negative on leukemic cells according to immunohistochemistry will be evaluated. | After course 6 (168 days) | |
Primary | MTD of 6,8-bis(benzylthio)octanoic acid when used in combination with bendamustine hydrochloride, defined as the dose level immediately below the dose level that induced a dose-limiting toxicity in < 2 patients | Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. | Up to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Recruiting |
NCT02445404 -
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
|
Phase 2 | |
Completed |
NCT01689220 -
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
|
Phase 1 | |
Terminated |
NCT01644253 -
Phase 1b Safety and Efficacy Study of TRU-016
|
Phase 1 | |
Completed |
NCT01435863 -
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
|
Phase 1 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Terminated |
NCT00441025 -
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00003196 -
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
|
N/A | |
Active, not recruiting |
NCT04312841 -
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
|
Phase 2 | |
Recruiting |
NCT04040491 -
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
|
Phase 4 | |
Terminated |
NCT01678443 -
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT02264613 -
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1/Phase 2 | |
Completed |
NCT02142530 -
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
|
Phase 1 | |
Terminated |
NCT01408043 -
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT00131937 -
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00791947 -
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT
|
Phase 2 | |
Recruiting |
NCT04880746 -
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
|
Phase 3 | |
Recruiting |
NCT03964480 -
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
|